Jitterbit Named Leader for 2026 Data Integration Data Quadrant Report by Info-Tech Research Group PepGen Announces Upcoming Data Presentations at the 2023 American Academy of Neurology Annual Meeting
BOSTON, April 17, 2023 (GLOBE NEWSWIRE) — PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company…
PepGen Announces Upcoming Data Presentations at the 2023 American Academy of Neurology Annual Meeting
BOSTON, April 17, 2023 (GLOBE NEWSWIRE) — PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company…
Vincerx Pharma Presents Preclinical Data on VIP236, a First-in-Class Small Molecule Drug Conjugate (SMDC), at the 2023 American Association for Cancer Research (AACR) Annual Meeting
VIP236, a SMDC with a novel optimized camptothecin (CPT) payload, demonstrated significant activity in patient-derived…
Vincerx Pharma Presents Preclinical Data on VIP236, a First-in-Class Small Molecule Drug Conjugate (SMDC), at the 2023 American Association for Cancer Research (AACR) Annual Meeting
VIP236, a SMDC with a novel optimized camptothecin (CPT) payload, demonstrated significant activity in patient-derived…
CymaBay Therapeutics to Present at the H.C. Wainwright BioConnect Investor Conference at NASDAQ
NEWARK, Calif., April 17, 2023 (GLOBE NEWSWIRE) — CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage…
CymaBay Therapeutics to Present at the H.C. Wainwright BioConnect Investor Conference at NASDAQ
NEWARK, Calif., April 17, 2023 (GLOBE NEWSWIRE) — CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage…
Achilles Therapeutics to Present at Chardan’s 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
LONDON, April 17, 2023 (GLOBE NEWSWIRE) — Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical…
Achilles Therapeutics to Present at Chardan’s 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
LONDON, April 17, 2023 (GLOBE NEWSWIRE) — Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical…
Enlivex Appoints Andrew Singer to its Board of Directors
Mr. Singer brings over 25 years of experience in biotechnology, corporate finance, mergers and acquisitions,…
Enlivex Appoints Andrew Singer to its Board of Directors
Mr. Singer brings over 25 years of experience in biotechnology, corporate finance, mergers and acquisitions,…
BioVie Announces Data Abstracts from NE3107 Phase 2 Trials Accepted for Presentation at AAN 2023
CARSON CITY, Nev., April 17, 2023 (GLOBE NEWSWIRE) — BioVie Inc. (NASDAQ: BIVI) (“BioVie” or…
BioVie Announces Data Abstracts from NE3107 Phase 2 Trials Accepted for Presentation at AAN 2023
CARSON CITY, Nev., April 17, 2023 (GLOBE NEWSWIRE) — BioVie Inc. (NASDAQ: BIVI) (“BioVie” or…
Innovation Pharmaceuticals Brilacidin Antifungal Research Published in Nature Communications
WAKEFIELD, MA, April 17, 2023 (GLOBE NEWSWIRE) — via NewMediaWire — Innovation Pharmaceuticals (OTCQB:IPIX) (“the…
Innovation Pharmaceuticals Brilacidin Antifungal Research Published in Nature Communications
WAKEFIELD, MA, April 17, 2023 (GLOBE NEWSWIRE) — via NewMediaWire — Innovation Pharmaceuticals (OTCQB:IPIX) (“the…
aTyr Pharma Presents Preclinical Research Demonstrating Treatment with ATYR2810 Inhibits Tumor Growth and Therapy Resistance in Highly Aggressive Cancers at the 2023 AACR Annual Meeting
Findings demonstrate effects of ATYR2810 in models of certain forms of lung and kidney cancers…
aTyr Pharma Presents Preclinical Research Demonstrating Treatment with ATYR2810 Inhibits Tumor Growth and Therapy Resistance in Highly Aggressive Cancers at the 2023 AACR Annual Meeting
Findings demonstrate effects of ATYR2810 in models of certain forms of lung and kidney cancers…
Candel Therapeutics Receives FDA Fast Track Designation for CAN-2409 in Non-Small Cell Lung Cancer
Fast track designation has the potential to facilitate the development and expedite the U.S. FDA…
Candel Therapeutics Receives FDA Fast Track Designation for CAN-2409 in Non-Small Cell Lung Cancer
Fast track designation has the potential to facilitate the development and expedite the U.S. FDA…
electroCore Provides Select First Quarter 2023 Financial Guidance
Record revenue of approximately $2.8M expected for the three months ended March 31, 2023; 46%…
electroCore Provides Select First Quarter 2023 Financial Guidance
Record revenue of approximately $2.8M expected for the three months ended March 31, 2023; 46%…